

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>Rouli Zhou <i>et al.</i></b>	)	Conf. No. <b>8365</b>
	)	
Application No. <b>10/540,539</b>	)	Group Art Unit: <b>1643</b>
	)	
Filed: <b>October 4, 2006</b>	)	Examiner: <b>Anne Gussow</b>
	)	
For: <b>Human Cancer-Relating Genes, the</b>	)	
<b>Products Encoded Thereby and Application</b>	)	
<b>Thereof</b>	)	

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.56 AND 1.97(c)**

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449 form. This Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Office Action or a Notice of Allowance. The Commissioner is hereby authorized to charge \$180.00, as specified by §1.17(p), to Deposit Account No. 50-0310 for this Information Disclosure Statement under the provisions of 37 C.F.R. §1.97(c). The listed documents are cited in the Examination Report issued in corresponding European Patent Application No. 03782072.7, a copy of which is attached.

The cited references, D1, WO 00/05367, and D2, Database EMBL Accession No. AY057051, "Homo sapiens lysosomal associated transmembrane protein 4 beta, variant 1 (LAPTM4B) mRNA, complete cds", were submitted to the Office on August 10, 2006. Accordingly, copies of the listed documents, D3 to D5, are attached herein. Identification of the listed references are not to be construed as an admission of Applicants or Attorneys for Applicants that the reference is available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review these references and make them of record in the present application by signing and returning the attached Information Disclosure Statement by Applicant.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

Dated: February 12, 2010

/Mark Sullivan/  
Mark J. Sullivan  
Reg. No. 54,478

**Customer No.: 009629**  
Morgan, Lewis & Bockius LLP  
1111 Pennsylvania Ave., NW  
Washington, DC 20004  
Tel: 202.739.3000  
Fax: 202.739.3001